The Effects of Anti-Platelet Agents in Preventing Coronary Stent Restenosis

Bae, Youl; Jeong, Myung Ho; Kim, Nam Ho; Park, Hyung Wook; Kang, Kyung Tae; Lee, Sang Hyun; Park, Woo Suck; Cho, Jang Hyun; Kim, Sung Hee; Kim, Joon‐Woo; Ahn, Young Keun; Cho, Jeong Gwan; Park, Chang Soo; Park, Jong Chun; Kang, Jung Chaee

doi:10.4070/kcj.1999.29.4.357

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13) After bare-metal stenting, cilostazol was comparable or superior to ticlopidine in reducing restenosis. 14) On a cost-effect analysis, treatment with cilostazol proved to be a cost-saving or dominant strategy in patients with coronary bare metal stent (BMS) implantation. 15) Although the introduction of DES has dramatically reduced neointimal hyperplasia and restenosis compared with BMS, several conditions still place patients at high risk for restenosis: diabetes mellitus, long lesions, and small vessel disease.…”

Section: Clinical Trials and Evidence For Clinical Effectsmentioning

confidence: 99%

The Clinical Effects of Cilostazol on Atherosclerotic Vascular Disease

Park

Kim

2008

Korean Circ J

View full text Add to dashboard Cite

Cilostazol inhibits phosphodiesterase III (PDE III), which is predominantly distributed to and regulates physiologic responses in platelets, cardiac muscle cells, vascular smooth muscle cells, and adipose cells. Clinically, it is well known as an antiplatelet agent that inhibits the platelet aggregation normally induced by collagen, 5'-adenosine diphosphase (ADP), epinephrine, and arachidonic acid. It also has pleotropic effects, including the prevention of restenosis after angioplasty and the promotion of peripheral vascular flow in patients with peripheral vascular diseases. In the drug-eluting stent era, it has emerged as an effective post-intervention anti-atherothrombotic agent and a useful agent for therapy in diabetic patients. The aim of this study was to review the mechanisms of action and clinical trial results associated with cilostazol in cardiovascular disease patients.

show abstract

Section: Clinical Trials and Evidence For Clinical Effectsmentioning

confidence: 99%